Provided by Tiger Trade Technology Pte. Ltd.

Akebia Therapeutics

0.9200
-0.0156-1.67%
Post-market: 0.9000-0.0200-2.17%17:44 EDT
Volume:2.08M
Turnover:1.91M
Market Cap:246.45M
PE:-11.83
High:0.9598
Open:0.9484
Low:0.9028
Close:0.9356
52wk High:4.08
52wk Low:0.8750
Shares:267.88M
Float Shares:259.80M
Volume Ratio:0.56
T/O Rate:0.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0777
EPS(LYR):-0.0208
ROE:-78.96%
ROA:2.02%
PB:9.00
PE(LYR):-44.26

Loading ...

Akebia Therapeutics grants new hire options for 8,400 shares at $1.02 each

Reuters
·
Jun 02

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 02

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

GlobeNewswire
·
May 28

Akebia Therapeutics Earnings Call: Vafseo Drives Transition

TIPRANKS
·
May 20

Akebia Therapeutics Balances Vafseo Momentum With Headwinds

TIPRANKS
·
May 09

Akebia Q1 revenue falls, net income misses analyst estimates on higher expenses

Reuters
·
May 07

Akebia Q1 FY26 turns to net loss of $9.1 million; revenue falls to $53.5 million

Reuters
·
May 07

Akebia Therapeutics Q1 EPS $(0.03), Inline, Sales $53.544M Beat $51.668M Estimate

Benzinga
·
May 07

Akebia Therapeutics Q1 Revenue USD 53.5 Million VS. Ibes Estimate USD 51.7 Million

THOMSON REUTERS
·
May 07

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

GlobeNewswire
·
May 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 07

Akebia Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview

Reuters
·
May 05

Akebia grants new hires options for 208,800 shares at $1.38 each

Reuters
·
May 05

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 05

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

GlobeNewswire
·
May 04

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights

GlobeNewswire
·
May 01

Akebia Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 29

Akebia Therapeutics (AKBA) Gets a Buy from Piper Sandler

TIPRANKS
·
Apr 24

Akebia Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 16

Akebia doses first participants in Phase 1 trial of AKB-9090 for acute kidney injury

Reuters
·
Apr 13